Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Akay, Aynur Pekcanlar, Kaya, Gamze Capa, Baykara, Burak, Demir, Yusuf, Özek, Handan, Alsen, Sevay, Eren, Mine Sencan, Emiroglu, Neslihan Inal, Ertay, Turkan, Ozturk, Yesim, Miral, Suha, Durak, Hatice, Tufan, Evren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657797/
https://www.ncbi.nlm.nih.gov/pubmed/26640376
http://dx.doi.org/10.2147/NDT.S87359
_version_ 1782402423278534656
author Akay, Aynur Pekcanlar
Kaya, Gamze Capa
Baykara, Burak
Demir, Yusuf
Özek, Handan
Alsen, Sevay
Eren, Mine Sencan
Emiroglu, Neslihan Inal
Ertay, Turkan
Ozturk, Yesim
Miral, Suha
Durak, Hatice
Tufan, Evren
author_facet Akay, Aynur Pekcanlar
Kaya, Gamze Capa
Baykara, Burak
Demir, Yusuf
Özek, Handan
Alsen, Sevay
Eren, Mine Sencan
Emiroglu, Neslihan Inal
Ertay, Turkan
Ozturk, Yesim
Miral, Suha
Durak, Hatice
Tufan, Evren
author_sort Akay, Aynur Pekcanlar
collection PubMed
description Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.
format Online
Article
Text
id pubmed-4657797
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46577972015-12-04 Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases Akay, Aynur Pekcanlar Kaya, Gamze Capa Baykara, Burak Demir, Yusuf Özek, Handan Alsen, Sevay Eren, Mine Sencan Emiroglu, Neslihan Inal Ertay, Turkan Ozturk, Yesim Miral, Suha Durak, Hatice Tufan, Evren Neuropsychiatr Dis Treat Short Report Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement. Dove Medical Press 2015-11-19 /pmc/articles/PMC4657797/ /pubmed/26640376 http://dx.doi.org/10.2147/NDT.S87359 Text en © 2015 Akay et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Short Report
Akay, Aynur Pekcanlar
Kaya, Gamze Capa
Baykara, Burak
Demir, Yusuf
Özek, Handan
Alsen, Sevay
Eren, Mine Sencan
Emiroglu, Neslihan Inal
Ertay, Turkan
Ozturk, Yesim
Miral, Suha
Durak, Hatice
Tufan, Evren
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
title Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
title_full Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
title_fullStr Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
title_full_unstemmed Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
title_short Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
title_sort atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot spect report of three cases
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657797/
https://www.ncbi.nlm.nih.gov/pubmed/26640376
http://dx.doi.org/10.2147/NDT.S87359
work_keys_str_mv AT akayaynurpekcanlar atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT kayagamzecapa atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT baykaraburak atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT demiryusuf atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT ozekhandan atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT alsensevay atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT erenminesencan atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT emirogluneslihaninal atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT ertayturkan atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT ozturkyesim atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT miralsuha atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT durakhatice atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases
AT tufanevren atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases

Ejemplares similares